Frank RÃ¶sch

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1183668/publications.pdf

Version: 2024-02-01

198	7,362	57758	74163
papers	citations	44 h-index	75 g-index

207	207	207	6521
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	First-in-Human Experience With 177Lu-DOTAGA.(SA.FAPi)2 Therapy in an Uncommon Case of Aggressive Medullary Thyroid Carcinoma Clinically Mimicking as Anaplastic Thyroid Cancer. Clinical Nuclear Medicine, 2022, 47, e444-e445.	1.3	14
2	Squaric Acid Bisphposphonates for Theranostics of Bone Metastasis â€“ the Easy DOTA-Zoledronate. Frontiers in Nuclear Medicine, 2022, 2, .	1.2	1
3	[⁶⁸Ga]Ga-THP-Pam: A Bisphosphonate PET Tracer with Facile Radiolabeling and Broad Calcium Mineral Affinity. Bioconjugate Chemistry, 2021, 32, 1276-1289.	3.6	17
4	A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGAZOL PET/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 134-142.	6.4	23
5	A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 942-944.	6.4	83
6	Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1915-1931.	6.4	88
7	On the consensus nomenclature rules for radiopharmaceutical chemistry â€“ Reconsideration of radiochemical conversion. Nuclear Medicine and Biology, 2021, 93, 19-21.	0.6	43
8	Evaluation of Safety and Dosimetry of ¹⁷⁷Lu-DOTA-ZOL for Therapy of Bone Metastases. Journal of Nuclear Medicine, 2021, 62, 1126-1132.	5.0	21
9	Impact of prompt gamma emission of 44Sc on quantification in preclinical and clinical PET systems. Applied Radiation and Isotopes, 2021, 170, 109599.	1.5	5
10	AAZTA5-squaramide ester competing with DOTA-, DTPA- and CHX-Aâ€³-DTPA-analogues: Promising tool for 177Lu-labeling of monoclonal antibodies under mild conditions. Nuclear Medicine and Biology, 2021, 96-97, 80-93.	0.6	7
11	In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi. Molecules, 2021, 26, 3482.	3.8	12
12	Squaric Acid-Based Radiopharmaceuticals for Tumor Imaging and Therapy. Bioconjugate Chemistry, 2021, 32, 1223-1231.	3.6	17
13	Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours. Nuklearmedizin - NuclearMedicine, 2021, 60, 344-354.	0.7	13
14	Development and in vitro evaluation of new bifunctional 89Zr-chelators based on the 6-amino-1,4-diazepane scaffold for immuno-PET applications. Nuclear Medicine and Biology, 2021, 102-103, 12-23.	0.6	6
15	Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach. Molecules, 2021, 26, 6332.	3.8	5
16	Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study. Thyroid, 2021, , .	4.5	31
17	New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress. Pharmaceuticals, 2021, 14, 1023.	3.8	38
18	First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2. Pharmaceuticals, 2021, 14, 1212.	3.8	52

#	Article	IF	Citations
19	Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time.. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 476-491.	1.0	1
20	Characterization of the serotonin 2A receptor selective PET tracer (R)-[18F]MH.MZ in the human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 355-365.	6.4	6
21	Synthesis and labeling of a squaric acid containing PSMA-inhibitor coupled to AAZTA5 for versatile labeling with 44Sc, 64Cu, 68Ga and 177Lu. Applied Radiation and Isotopes, 2020, 156, 108867.	1.5	20
22	The Use of the Macrocyclic Chelator DOTA in Radiochemical Separations. European Journal of Inorganic Chemistry, 2020, 2020, 36-56.	2.0	44
23	Pharmacokinetic evaluation of [18F]PR04.MZ for PET/CT imaging and quantification of dopamine transporters in the human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1927-1937.	6.4	11
24	Gallium-68 and scandium-44 labelled radiotracers based on curcumin structure linked to bifunctional chelators: Synthesis and characterization of potential PET radiotracers. Journal of Inorganic Biochemistry, 2020, 204, 110954.	3.5	17
25	Evaluation of [68Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: comparison with [68Ga]Ga-DOTA-NOC PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 860-869.	6.4	14
26	Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 19.	3.9	61
27	Targeting of Immune Cells with Trimannosylated Liposomes. Advanced Therapeutics, 2020, 3, 1900185.	3.2	11
28	Synthesis, Labeling and Preclinical Evaluation of a Squaric Acid Containing PSMA Inhibitor Labeled with ⁶⁸Ga: A Comparison with PSMAâ€11 and PSMAâ€617. ChemMedChem, 2020, 15, 695-704.	3.2	11
29	[68Ga]Ga-DATA5m.SA.FAPi PET/CT: Specific Tracer-uptake in Focal Nodular Hyperplasia and potential Role in Liver Tumor Imaging. Nuklearmedizin - NuclearMedicine, 2020, 59, 387-389.	0.7	16
30	[177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results. EJNMMI Research, 2020, 10, 130.	2.5	13
31	Image quality analysis of 44Sc on two preclinical PET scanners: a comparison to 68Ga. EJNMMI Physics, 2020, 7, 16.	2.7	23
32	68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 28.	3.9	19
33	Effect of the versatile bifunctional chelator AAZTA5 on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor antagonist. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 29.	3.9	6
34	Mild and efficient ⁶⁴Cu labeling of perhydro-1, 4-diazepine derivatives for potential use with large peptides, proteins and antibodies. Radiochimica Acta, 2020, 108, 555-563.	1.2	5
35	[177Lu]Lu-DOTA-zoledronate therapy â€“ first application in a patient with primary osseous metastatic bronchial carcinoma. Nuklearmedizin - NuclearMedicine, 2020, 59, 281-283.	0.7	4
36	Measurement of the laser resonance ionization efficiency for lutetium. Radiochimica Acta, 2019, 107, 653-661.	1.2	14

#	Article	IF	Citations
37	Instant kit preparation of 68Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [68Ga]Ga-DATA-TOC. EJNMMI Research, 2019, 9, 48.	2.5	20
38	Evaluation of the inverse electron demand Diels-Alder reaction in rats using a scandium-44-labelled tetrazine for pretargeted PET imaging. EJNMMI Research, 2019, 9, 49.	2.5	24
39	From Bench to Bedsideâ€"The Bad Berka Experience With First-in-Human Studies. Seminars in Nuclear Medicine, 2019, 49, 422-437.	4.6	30
40	AAZTA5/AAZTA5-TOC: synthesis and radiochemical evaluation with 68Ga, 44Sc and 177Lu. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 18.	3.9	28
41	Preliminary results of biodistribution and dosimetric analysis of [68Ga]Ga-DOTAZOL: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseases. Annals of Nuclear Medicine, 2019, 33, 404-413.	2.2	29
42	Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer. International Journal of Medical Sciences, 2019, 16, 1188-1198.	2.5	19
43	Copper-catalyzed click reactions: quantification of retained copper using ⁶⁴Cu-spiked Cu(I), exemplified for CuAAC reactions on liposomes. Radiochimica Acta, 2019, 107, 547-554.	1.2	1
44	Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results. EJNMMI Research, 2019, 9, 102.	2.5	20
45	[44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma. Clinical Nuclear Medicine, 2018, 43, 323-330.	1.3	22
46	Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma. Clinical Nuclear Medicine, 2018, 43, 486-491.	1.3	24
47	Comparison of Linear and Hyperbranched Polyether Lipids for Liposome Shielding by ¹⁸F-Radiolabeling and Positron Emission Tomography. Biomacromolecules, 2018, 19, 2506-2516.	5.4	20
48	Structureâ€"Function Evaluation of Imidazopyridine Derivatives Selective for Î´-Subunit-Containing Î³-Aminobutyric Acid Type A (GABAA) Receptors. Journal of Medicinal Chemistry, 2018, 61, 1951-1968.	6.4	21
49	Long-term biodistribution study of HPMA- ran -LMA copolymers in vivo by means of 131 I-labeling. Nuclear Medicine and Biology, 2018, 58, 59-66.	0.6	7
50	Labeling of DOTA-conjugated HPMA-based polymers with trivalent metallic radionuclides for molecular imaging. EJNMMI Research, 2018, 8, 16.	2.5	9
51	Nuclear transformations and radioactive emissions: Part Iâ€"primary transformation pathways of unstable nuclei. ChemTexts, 2018, 4, 1.	1.9	0
52	Nuclear transformations and radioactive emissions: Part IIâ€"secondary transitions and post-effects. ChemTexts, 2018, 4, 1.	1.9	0
53	NMR Hyperpolarization of Established PET Tracers. ChemistrySelect, 2018, 3, 5176-5184.	1.5	4
54	Comparison Study of Two Differently Clicked 18F-Folatesâ€"Lipophilicity Plays a Key Role. Pharmaceuticals, 2018, 11, 30.	3.8	9

#	Article	IF	Citations
55	Improved Efficacy of Synthesizing *M^{III}-Labeled DOTA Complexes in Binary Mixtures of Water and Organic Solvents. A Combined Radio- and Physicochemical Study. Inorganic Chemistry, 2018, 57, 6107-6117.	4.0	21
56	In vivo Evaluation of [²²⁵Ac]Ac-DOTA^{ZOL} for Î±-Therapy of Bone Metastases. Current Radiopharmaceuticals, 2018, 11, 223-230.	0.8	21
57	DATATOC: a novel conjugate for kit-type 68Ga labelling of TOC at ambient temperature. EJNMMI Radiopharmacy and Chemistry, 2017, 1, 4.	3.9	41
58	Improved radiolabeling of DOTATOC with trivalent radiometals for clinical application by addition of ethanol. EJNMMI Radiopharmacy and Chemistry, 2017, 1, 6.	3.9	24
59	Optimization of Labeling PSMA^{HBED} with Ethanol-Postprocessed ⁶⁸Ga and Its Quality Control Systems. Journal of Nuclear Medicine, 2017, 58, 432-437.	5.0	14
60	Equilibrium, Kinetic and Structural Properties of Gallium(III) and Some Divalent Metal Complexes Formed with the New DATA^m and DATA^{5m} Ligands. Chemistry - A European Journal, 2017, 23, 10358-10371.	3.3	25
61	Novel bifunctional DATA chelator for quick access to site-directed PET ⁶⁸Ga-radiotracers: preclinical proof-of-principle with [Tyr³]octreotide. Dalton Transactions, 2017, 46, 14584-14590.	3.3	15
62	Evaluation of bone-seeking novel radiotracer 68Ga-NO2AP-Bisphosphonate for the detection of skeletal metastases in carcinoma breast. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 41-49.	6.4	36
63	Clinical Translation and First In-Human Use of [⁴⁴Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer. Theranostics, 2017, 7, 4359-4369.	10.0	94
64	Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases. Pharmaceuticals, 2017, 10, 45.	3.8	44
65	The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y. Pharmaceuticals, 2017, 10, 56.	3.8	114
66	Labeling and preliminary in vivo assessment of niobium-labeled radioactive species: A proof-of-concept study. Nuclear Medicine and Biology, 2016, 43, 280-287.	0.6	12
67	A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting. Nuclear Medicine and Biology, 2016, 43, 670-678.	0.6	18
68	Bifunctional Gallium-68 Chelators: Past, Present, and Future. Seminars in Nuclear Medicine, 2016, 46, 373-394.	4.6	80
69	Orthogonal Click Conjugation to the Liposomal Surface Reveals the Stability of the Lipid Anchorage as Crucial for Targeting. Chemistry - A European Journal, 2016, 22, 11578-11582.	3.3	20
70	177Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment. EJNMMI Research, 2016, 6, 5.	2.5	36
71	Direct flow separation strategy, to isolate no-carrier-added ⁹⁰Nb from irradiated Mo or Zr targets. Radiochimica Acta, 2016, 104, 625-634.	1.2	7
72	Approaching â€˜Kitâ€Typeâ€™ Labelling with ⁶⁸Ga: The DATA Chelators. ChemMedChem, 2015, 10, 1019-1026.	3.2	56

#	Article	IF	Citations
73	Imaging Nigrostriatal Dopaminergic Deficit in Holmes Tremor with 18F-PR04.MZ-PET/CT. Clinical Nuclear Medicine, 2015, 40, 740-741.	1.3	9
74	Fate of Linear and Branched Polyether-Lipids In Vivo in Comparison to Their Liposomal Formulations by ¹⁸F-Radiolabeling and Positron Emission Tomography. Biomacromolecules, 2015, 16, 842-851.	5.4	19
75	Promoting Experimental Problem-solving Ability in Sixth-grade Students Through Problem-oriented Teaching of Ecology: Findings of an intervention study in a complex domain. International Journal of Science Education, 2015, 37, 577-598.	1.9	11
76	Cation exchange-based post-processing of 68Ga-eluate: A comparison of three solvent systems for labelling of DOTATOC, NO2APBP and DATAm. Applied Radiation and Isotopes, 2015, 98, 54-59.	1.5	21
77	Selective binding to monoamine oxidase A: In vitro and in vivo evaluation of 18F-labeled Î²-carboline derivatives. Bioorganic and Medicinal Chemistry, 2015, 23, 612-623.	3.0	15
78	Behavior of Actinium, Alkaline, and Rare Earth Elements in Sr-Resin/Mineral Acid Systems. Solvent Extraction and Ion Exchange, 2015, 33, 496-509.	2.0	11
79	Synthesis and Preliminary in Vivo Evaluation of Well-Dispersed Biomimetic Nanocrystalline Apatites Labeled with Positron Emission Tomographic Imaging Agents. ACS Applied Materials & Interfaces, 2015, 7, 10623-10633.	8.0	42
80	Development of a [¹⁷⁷Lu]BPAMD Labeling Kit and an Automated Synthesis Module for Routine Bone Targeted Endoradiotherapy. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 94-99.	1.0	18
81	Gallium(III) complexes of NOTAâ€bis (phosphonate) conjugates as PET radiotracers for bone imaging. Contrast Media and Molecular Imaging, 2015, 10, 122-134.	0.8	50
82	Ethanol-Based Post-processing of Generator-Derived ⁶⁸Ga Toward Kit-Type Preparation of ⁶⁸Ga-Radiopharmaceuticals. Journal of Nuclear Medicine, 2014, 55, 1023-1028.	5.0	56
83	Desferrioxamine as an appropriate chelator for 90Nb: Comparison of its complexation properties for M-Df-Octreotide (M=Nb, Fe, Ga, Zr). Nuclear Medicine and Biology, 2014, 41, 721-727.	0.6	17
84	Positron Emission Tomography in CNS Drug Discovery and Drug Monitoring. Journal of Medicinal Chemistry, 2014, 57, 9232-9258.	6.4	129
85	Evaluation of P-glycoprotein (abcb1a/b) modulation of [18F]fallypride in MicroPET imaging studies. Neuropharmacology, 2014, 84, 152-158.	4.1	13
86	68Ge content quality control of 68Ge/68Ga-generator eluates and 68Ga radiopharmaceuticals â€“ A protocol for determining the 68Ge content using thin-layer chromatography. Applied Radiation and Isotopes, 2014, 91, 92-96.	1.5	4
87	PEGylation of HPMA-based block copolymers enhances tumor accumulation in vivo : A quantitative study using radiolabeling and positron emission tomography. Journal of Controlled Release, 2013, 172, 77-85.	9.9	60
88	Quantitative online isolation of 68Ge from 68Ge/68Ga generator eluates for purification and immediate quality control of breakthrough. Applied Radiation and Isotopes, 2013, 82, 45-48.	1.5	10
89	Radiolabelling and preliminary evaluation of 68Ga-tetrapyrrole derivatives as potential tracers for PET. Nuclear Medicine and Biology, 2013, 40, 280-288.	0.6	29
90	Twoâ€step radiosynthesis of [¹⁸F]FEâ€Î²â€CIT and [¹⁸F]PR04.MZ. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 356-359.	1.0	7

#	Article	IF	Citations
91	In vivo comparison of DOTA based 68Ga-labelled bisphosphonates for bone imaging in non-tumour models. Nuclear Medicine and Biology, 2013, 40, 823-830.	0.6	38
92	Structure and stability of hexadentate complexes of ligands based on AAZTA for efficient PET labelling with gallium-68. Chemical Communications, 2013, 49, 579-581.	4.1	75
93	Imaging of Protein Synthesis: In Vitro and In Vivo Evaluation of 44Sc-DOTA-Puromycin. Molecular Imaging and Biology, 2013, 15, 79-86.	2.6	33
94	HPMA-LMA Copolymer Drug Carriers in Oncology: An in Vivo PET Study to Assess the Tumor Line-Specific Polymer Uptake and Body Distribution. Biomacromolecules, 2013, 14, 3091-3101.	5.4	30
95	Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability. International Journal of Neuropsychopharmacology, 2013, 16, 745-754.	2.1	25
96	Surrogate markers for cerebral blood flow correlate with [¹⁸F]â€fallypride binding potential at dopamine D_{2/3} receptors in human striatum. Synapse, 2013, 67, 199-203.	1.2	21
97	Automated synthesis and purification of [¹⁸F]fluoroâ€[diâ€deutero]methyl tosylate. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 360-363.	1.0	9
98	PET Imaging of the Impact of Extracellular pH and MAP Kinases on the p-Glycoprotein (Pgp) Activity. Advances in Experimental Medicine and Biology, 2013, 765, 279-286.	1.6	9
99	⁹⁰Nb â€“ aÂpotential PET nuclide: production and labeling of monoclonal antibodies. Radiochimica Acta, 2012, 100, 857-864.	1.2	25
100	A concise synthesis procedure to furnish multi-gram amounts of hexadentate, bivalent DO2A-based chelators. RSC Advances, 2012, 2, 7156.	3.6	6
101	Direct radiofluorination of [¹⁸F]MH.MZ for 5â€HT_{2A} receptor molecular imaging with PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2012, 55, 354-358.	1.0	6
102	Radiolabeling of DOTATOC with the long-lived positron emitter 44Sc. Applied Radiation and Isotopes, 2012, 70, 974-979.	1.5	69
103	Characterisation of [11C]PR04.MZ in Papio anubis baboon: A selective high-affinity radioligand for quantitative imaging of the dopamine transporter. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 679-682.	2.2	6
104	Rapid radiosynthesis of [¹¹C] and [¹⁴C]azelaic, suberic, and sebacic acids for in vivo mechanistic studies of systemic acquired resistance in plants. Journal of Labelled Compounds and Radiopharmaceuticals, 2012, 55, 39-43.	1.0	17
105	Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS. Dalton Transactions, 2011, 40, 6104.	3.3	148
106	Opiate-Induced Dopamine Release Is Modulated by Severity of Alcohol Dependence: An [18F]Fallypride Positron Emission Tomography Study. Biological Psychiatry, 2011, 70, 770-776.	1.3	34
107	Modifying the Body Distribution of HPMA-Based Copolymers by Molecular Weight and Aggregate Formation. Biomacromolecules, 2011, 12, 2841-2849.	5.4	72
108	Potential use of 68Ga-apo-transferrin as a PET imaging agent for detecting Staphylococcus aureus infection. Nuclear Medicine and Biology, 2011, 38, 393-398.	0.6	37

#	Article	IF	Citations
109	The applicability of SRTM in [18F]fallypride PET investigations: Impact of scan durations. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 1958-1966.	4.3	35
110	Assessing p-Glycoprotein (Pgp) Activity In Vivo Utilizing 68Gaâ€“Schiff Base Complexes. Molecular Imaging and Biology, 2011, 13, 985-994.	2.6	11
111	HPMA Based Amphiphilic Copolymers Mediate Central Nervous Effects of Domperidone. Macromolecular Rapid Communications, 2011, 32, 712-717.	3.9	31
112	Macromol. Rapid Commun. 9â€“10/2011. Macromolecular Rapid Communications, 2011, 32, .	3.9	1
113	A methodical ⁶⁸Gaâ€labelling study of DO2Aâ€(butylâ€•<scp>l</scp>â€tyrosine)₂ with cationâ€exchanger postâ€processed ⁶⁸Ga: practical aspects of radiolabelling. Contrast Media and Molecular Imaging, 2011, 6, 492-498.	0.8	19
114	Comparison of different phosphorus-containing ligands complexing68Ga for PET-imaging of bone metabolism. Radiochimica Acta, 2011, 99, 43-51.	1.2	35
115	P-Glycoprotein Influence on the Brain Uptake of a 5-HT_{2A} Ligand: [¹⁸F]MH.MZ. Neuropsychobiology, 2011, 63, 183-190.	1.9	5
116	The Renaissance of the 68Ge/68Ga Radionuclide Generator Initiates New Developments in 68Ga Radiopharmaceutical Chemistry. Current Topics in Medicinal Chemistry, 2010, 10, 1633-1668.	2.1	169
117	Reply: Impurity in 68Ga-Peptide Preparation Using Processed Generator Eluate. Journal of Nuclear Medicine, 2010, 51, 495.2-496.	5.0	1
118	PET/CT imaging of osteoblastic bone metastases with 68Ga-bisphosphonates: first human study. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 834-834.	6.4	80
119	Activation of P-glycoprotein (Pgp)-mediated drug efflux by extracellular acidosis: in vivo imaging with 68Ga-labelled PET tracer. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1935-1942.	6.4	26
120	Predicting the in vivo release from a liposomal formulation by IVIVC and non-invasive positron emission tomography imaging. European Journal of Pharmaceutical Sciences, 2010, 41, 71-77.	4.0	14
121	The DAT Ligand [¹⁸F]PR17.MZ Mirrors the inâ€...vivo Pharmacokinetic Profile of [¹¹C]Cocaine with Significantly Improved Monoamine Transporter Selectivity. ChemMedChem, 2010, 5, 1686-1688.	3.2	3
122	A Triazacyclononaneâ€Based Bifunctional Phosphinate Ligand for the Preparation of Multimeric ⁶⁸Ga Tracers for Positron Emission Tomography. Chemistry - A European Journal, 2010, 16, 7174-7185.	3.3	138
123	72/74As-labeling of HPMA based polymers for long-term in vivo PET imaging. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5454-5458.	2.2	40
124	Research Letter: Structural Combination of Established 5â€HT_{2A} Receptor Ligands: New Aspects of the Binding Mode. Chemical Biology and Drug Design, 2010, 76, 361-366.	3.2	5
125	Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. International Journal of Neuropsychopharmacology, 2010, 13, 951-960.	2.1	33
126	Efficient post-processing of aqueous generator eluates facilitates 68Ga-labelling under anhydrous conditions. Radiochimica Acta, 2010, 98, .	1.2	19

#	Article	IF	Citations
127	Studies towards the development of lipophilic bifunctional N₃S₃ chelators for ⁶⁸Ga. Radiochimica Acta, 2010, 98, 519-523.	1.2	4
128	Separation and purification of no-carrier-added arsenic from bulk amounts of germanium for use in radiopharmaceutical labelling. Radiochimica Acta, 2010, 98, 807-812.	1.2	27
129	A 44Ti/44Sc radionuclide generator for potential application of 44Sc-based PET-radiopharmaceuticals. Radiochimica Acta, 2010, 98, .	1.2	98
130	Automated GMP production of [11C]PR04.MZ via the captive solvent method and PET studies in non-human primates: A promising tracer for extrastriatal DAT imaging. NeuroImage, 2010, 52, S117.	4.2	0
131	Equilibrium in [18F]fallypride PET. NeuroImage, 2010, 52, S160.	4.2	0
132	18F-Labeling and evaluation of novel MDL 100907 derivatives as potential 5-HT2A antagonists for molecular imaging. Nuclear Medicine and Biology, 2010, 37, 487-495.	0.6	23
133	Exâ€…vivo and inâ€…vivo Evaluation of [¹⁸F]PR04.MZ in Rodents: A Selective Dopamine Transporter Imaging Agent. ChemMedChem, 2009, 4, 1480-1487.	3.2	16
134	Synthesis of novel WAY 100635 derivatives containing a norbornene group and radiofluorination of [18F]AH1.MZ as a serotonin 5-HT1Areceptor antagonist for molecular imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2009, 52, 201-207.	1.0	8
135	Synthesis and radiosynthesis of N5-[18F]fluoroethyl-Pirenzepine and its metabolite N5-[18F]fluoroethyl-LS 75. Journal of Labelled Compounds and Radiopharmaceuticals, 2009, 52, n/a-n/a.	1.0	8
136	Efficient microwave-assisted direct radiosynthesis of [18F]PR04.MZ and [18F]LBT999: Selective dopamine transporter ligands for quantitative molecular imaging by means of PET. Bioorganic and Medicinal Chemistry, 2009, 17, 7630-7634.	3.0	13
137	[68Ga]Ga-DO2A-(OBu-l-tyr)2: Synthesis, 68Ga-radiolabeling and in vitro studies of a novel 68Ga-DO2A-tyrosine conjugate as potential tumor tracer for PET. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3498-3501.	2.2	21
138	[11C]PR04.MZ, a promising DAT ligand for low concentration imaging: Synthesis, efficient 11C-O-methylation and initial small animal PET studies. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4343-4345.	2.2	6
139	Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. Bioorganic and Medicinal Chemistry, 2009, 17, 2989-3002.	3.0	38
140	Radioactive Labeling of Defined HPMA-Based Polymeric Structures Using [¹⁸F]FETos for In Vivo Imaging by Positron Emission Tomography. Biomacromolecules, 2009, 10, 1697-1703.	5.4	99
141	Preliminary in vivo and ex vivo evaluation of the 5-HT2A imaging probe [18F]MH.MZ. Nuclear Medicine and Biology, 2009, 36, 447-454.	0.6	25
142	Ratio of dopamine synthesis capacity to D2 receptor availability in ventral striatum correlates with central processing of affective stimuli. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1147-1158.	6.4	18
143	Total synthesis and evaluation of [18F]MHMZ. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1515-1519.	2.2	33
144	NODAPA-OH and NODAPA-(NCS)n: Synthesis, 68Ga-radiolabelling and in vitro characterisation of novel versatile bifunctional chelators for molecular imaging. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5364-5367.	2.2	49

#	Article	IF	Citations
145	A convenient chemo-enzymatic synthesis and 18F-labelling of both enantiomers of trans-1-toluenesulfonyloxymethyl-2-fluoromethyl-cyclopropane. Organic and Biomolecular Chemistry, 2008, 6, 4567.	2.8	19
146	Validation of 68Ge/68Ga generator processing by chemical purification for routine clinical application of 68Ga-DOTATOC. Nuclear Medicine and Biology, 2008, 35, 721-724.	0.6	93
147	Vascular Imaging of Solid Tumors in Rats with a Radioactive Arsenic-Labeled Antibody that Binds Exposed Phosphatidylserine. Clinical Cancer Research, 2008, 14, 1377-1385.	7.0	98
148	closo-Borane Conjugated Regulatory Peptides Retain High Biological Affinity: Synthesis of closo-Borane Conjugated Tyr³-Octreotate Derivatives for BNCT. Bioconjugate Chemistry, 2008, 19, 1796-1802.	3.6	29
149	Association of Low Striatal Dopamine D₂Receptor Availability With Nicotine Dependence Similar to That Seen With Other Drugs of Abuse. American Journal of Psychiatry, 2008, 165, 507-514.	7.2	189
150	Brain and Plasma Pharmacokinetics of Aripiprazole in Patients With Schizophrenia: An [¹⁸F]Fallypride PET Study. American Journal of Psychiatry, 2008, 165, 988-995.	7.2	139
151	A 140Nd/140Pr radionuclide generator based on physico-chemical transitions in 140Pr complexes after electron capture decay of 140Nd-DOTA. Radiochimica Acta, 2007, 95, 319-327.	1.2	31
152	Radiolanthanides in endoradiotherapy: an overview. Radiochimica Acta, 2007, 95, 303-311.	1.2	48
153	Asymmetry in dopamine D2/3 receptors of caudate nucleus is lost with age. NeuroImage, 2007, 34, 870-878.	4.2	65
154	Processing of Generator-Produced 68Ga for Medical Application. Journal of Nuclear Medicine, 2007, 48, 1741-1748.	5.0	445
155	In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D2-like dopamine receptors. Bioorganic and Medicinal Chemistry, 2007, 15, 6819-6829.	3.0	27
156	Synthesis of131I-Labeled Glucose-Conjugated Inhibitors ofO6-Methylguanine-DNA Methyltransferase (MGMT) and Comparison with Nonconjugated Inhibitors as Potential Tools for in Vivo MGMT Imaging. Journal of Medicinal Chemistry, 2006, 49, 263-272.	6.4	26
157	High opiate receptor binding potential in the human lateral pain system. NeuroImage, 2006, 30, 692-699.	4.2	157
158	Net influx of plasma 6-[18F]fluoro-l-DOPA (FDOPA) to the ventral striatum correlates with prefrontal processing of affective stimuli. European Journal of Neuroscience, 2006, 24, 305-313.	2.6	48
159	Decreased Dopamine D2/D3-Receptor Binding in Temporal Lobe Epilepsy: An [18F]Fallypride PET Study. Epilepsia, 2006, 47, 1392-1396.	5.1	92
160	Preliminary assessment of the imaging capability of the YAPâ€“(S)PET small animal scanner in neuroscience. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2006, 569, 488-491.	1.6	4
161	Application of tris-allyl-DOTA in the preparation of DOTAâ€“peptide conjugates. Tetrahedron Letters, 2006, 47, 5985-5988.	1.4	22
162	The Striatal and Extrastriatal D2/D3 Receptor-Binding Profile of Clozapine in Patients with Schizophrenia. Neuropsychopharmacology, 2006, 31, 1027-1035.	5.4	96

#	Article	IF	Citations
163	Acute Blood Pressure Effects and Chronic Hypotensive Action of Calcimimetics in Uremic Rats. Journal of the American Society of Nephrology: JASN, 2006, 17, 655-662.	6.1	65
164	Correlation of Alcohol Craving With Striatal Dopamine Synthesis Capacity and D2/3Receptor Availability: A Combined [18F]DOPA and [18F]DMFP PET Study in Detoxified Alcoholic Patients. American Journal of Psychiatry, 2005, 162, 1515-1520.	7.2	253
165	A no-carrier-added 72Se/72As radionuclide generator based on solid phase extraction. Radiochimica Acta, 2005, 93, .	1.2	39
166	Inhibition of O6-Methylguanine-DNA Methyltransferase by Glucose-Conjugated Inhibitors: Comparison with Nonconjugated Inhibitors and Effect on Fotemustine and Temozolomide-Induced Cell Death. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 585-593.	2.5	54
167	A no-carrier-added 72Se/72As radionuclide generator based on distillation. Radiochimica Acta, 2004, 92, 245-249.	1.2	33
168	The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1128-35.	6.4	51
169	Synthesis of a technetium-99m labelledL-tyrosine derivative with thefac-99mTc(I)(CO)3-core using a simple kit-procedure. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 477-483.	1.0	4
170	Synthesis and in vitro evaluation of (S)-2-([11C]methoxy)-4-[3-methyl-1-(2-piperidine-1-yl-phenyl)-butyl-carbamoyl]-benzoic acid ([11C]methoxy-repaglinide): a potential Î²-cell imaging agent. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5205-5209.	2.2	34
171	Limiting transport properties and hydration numbers of actinyl ions in pure water. Radiochimica Acta, 2004, 92, .	1.2	22
172	High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. International Journal of Neuropsychopharmacology, 2004, 7, 421-430.	2.1	50
173	Correlation Between Dopamine D2 Receptors in the Ventral Striatum and Central Processing of Alcohol Cues and Craving. American Journal of Psychiatry, 2004, 161, 1783-1789.	7.2	341
174	Synthesis of a Tyr3-octreotate conjugated closo-carborane [HC2B10H10]: a potential compound for boron neutron capture therapy. Tetrahedron Letters, 2003, 44, 9143-9145.	1.4	27
175	Synthesis and evaluation of 5,7-dichloro-4-(3-{4-[4-(2-[18F]fluoroethyl)-piperazin-1-yl]-phenyl}-ureido)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid as a potential NMDA ligand to study glutamatergic neurotransmission in vivo. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 645-659.	1.0	16
176	Syntheses of novelN-([18F]fluoroalkyl)-N-nitroso-4-methyl-benzenesulfonamides and decomposition studies of corresponding19F- and bromo-analogues: potential new compounds for the18F-labelling of radiopharmaceuticals. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 959-977.	1.0	11
177	Synthesis and evaluation of tritium labelled 10-methylgalanthamine iodide: a novel compound to examine the mechanism of interaction of galanthamine derivatives with the nicotinic acetylcholine receptors. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 1117-1125.	1.0	3
178	Efficient alkali iodide promoted 18F-fluoroethylations with 2-[18F]fluoroethyl tosylate and 1-bromo-2-[18F]fluoroethane. Tetrahedron Letters, 2003, 44, 9165-9167.	1.4	38
179	Synthesis and preliminary evaluation of (R,R)(S,S) 5-(2-(2-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylethylamino)-1-hydroxyethyl)-benzene-1,3-diol ([18F]FEFE) for the in vivo visualisation and quantification of the Î²2-adrenergic receptor status in lung. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2687-2692.	2.2	9
180	Limiting transport properties of lanthanide and actinide ions in pure water. Radiochimica Acta, 2003, 91, 473-478.	1.2	24

#	Article	IF	Citations
181	Complex formation of Tb3+ with glycolate, D-gluconate and Î±-isosaccharinate in neutral aqueous perchlorate solutions. Radiochimica Acta, 2003, 91, 599-602.	1.2	6
182	Cross section data for the production of the positron emitting niobium isotope 90Nb via the 90Zr(p,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.2	38
183	Electrochemical separation and purification of yttrium-86. Radiochimica Acta, 2002, 90, 225-228.	1.2	47
184	Radiochemical separation of no-carrier-added radioniobium from zirconiu targets for application of 90Nb-labelled compounds. Radiochimica Acta, 2002, 90, 411-415.	1.2	17
185	Radiosynthesis of 1-(4-(2-[18F]fluoroethoxy)benzenesulfonyl)-3-butyl urea: a potentialÎ²-cell imaging agent. Journal of Labelled Compounds and Radiopharmaceuticals, 2002, 45, 763-774.	1.0	19
186	An approach to the evaluation of the activity of the DNA repair enzyme O6-methylguanine-DNA-methyl-transferase in tumor tissue in vivo: syntheses of 6-benzyloxy-9-(2-[18F]fluoroethyl)-9H-purin-2-yl-amine and 6-benzyloxy-7-(2-[18F]fluoroethyl)-7H-purin-2-yl-amine. Applied Radiation and Isotopes, 2002, 56, 511-517.	1.5	8
187	Synthesis of 2-amino-6-(2-[18F]fluoro-pyridine-4-ylmethoxy)-9-(octyl-Î²-d-glucosyl)-purine: a novel radioligand for positron emission tomography studies of the O6-methylguanine-DNA methyltransferase (MGMT) status of tumour tissue. Tetrahedron Letters, 2002, 43, 6301-6304.	1.4	24
188	[18 F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1463-1470.	6.4	46
189	Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1743-1750.	6.4	127
190	Radiosynthesis of		